Embla Medical hf Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Embla Medical hf kazanç ve gelirin sırasıyla yıllık 16.9% ve 8.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.9%

Kazanç büyüme oranı

17.8%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	22.6%
Gelir büyüme oranı	8.5%
Gelecekteki özkaynak getirisi	11.2%
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0FIW - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,022	106	111	155	5
12/31/2025	939	92	97	137	5
12/31/2024	864	74	24	107	5
9/30/2024	840	69	69	111	N/A
6/30/2024	820	61	54	96	N/A
3/31/2024	804	57	47	93	N/A
12/31/2023	786	58	52	94	N/A
9/30/2023	766	52	43	82	N/A
6/30/2023	750	45	37	72	N/A
3/31/2023	730	43	28	57	N/A
12/31/2022	719	43	35	61	N/A
9/30/2022	715	47	49	76	N/A
6/30/2022	719	57	50	79	N/A
3/31/2022	728	62	69	96	N/A
12/31/2021	719	64	74	101	N/A
9/30/2021	701	50	54	77	N/A
6/30/2021	692	48	63	84	N/A
3/31/2021	637	11	62	82	N/A
12/31/2020	630	6	68	92	N/A
9/30/2020	639	20	65	92	N/A
6/30/2020	635	19	78	109	N/A
3/31/2020	680	59	75	109	N/A
12/31/2019	686	66	63	95	N/A
9/30/2019	675	83	72	102	N/A
6/30/2019	652	85	55	84	N/A
3/31/2019	631	83	47	76	N/A
12/31/2018	613	80	39	69	N/A
9/30/2018	599	69	48	78	N/A
6/30/2018	593	64	N/A	71	N/A
3/31/2018	579	58	N/A	72	N/A
12/31/2017	569	58	N/A	74	N/A
9/30/2017	553	49	N/A	64	N/A
6/30/2017	543	51	N/A	68	N/A
3/31/2017	538	52	N/A	61	N/A
12/31/2016	521	51	N/A	66	N/A
9/30/2016	507	49	N/A	69	N/A
6/30/2016	495	50	N/A	65	N/A
3/31/2016	483	51	N/A	74	N/A
12/31/2015	483	51	N/A	66	N/A
9/30/2015	488	54	N/A	67	N/A
6/30/2015	497	55	N/A	77	N/A
3/31/2015	502	57	N/A	79	N/A
12/31/2014	509	59	N/A	85	N/A
9/30/2014	509	58	N/A	86	N/A
6/30/2014	487	55	N/A	82	N/A
3/31/2014	460	46	N/A	71	N/A
12/31/2013	436	40	N/A	66	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0FIW 'nin tahmini kazanç büyümesi (yıllık 16.9% ) tasarruf oranının ( 2.1% ) üzerindedir.

Kazançlar ve Piyasa: 0FIW şirketinin kazançlarının (yıllık 16.9% ) UK pazarından (yıllık 14.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 0FIW şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 0FIW şirketinin gelirinin (yıllık 8.5% ) UK pazarından (yıllık 3.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0FIW şirketinin gelirinin (yıllık 8.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0FIW 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.2 %).

Embla Medical hf Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Össur hf. Provides Earnings Guidance for the Year 2024

Össur hf. Reaffirms Financial Guidance for the Year 2023

Össur hf. Provides Earnings Guidance for the Year 2023

Össur hf. Revises Earnings Guidance for the Year 2022

Recent updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Less than half of directors are independent

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. Provides Earnings Guidance for the Year 2024

Less than half of directors are independent

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Less than half of directors are independent

Össur hf. Reaffirms Financial Guidance for the Year 2023

Less than half of directors are independent

Össur hf. Announces Executive Changes

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Less than half of directors are independent

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Less than half of directors are independent

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Less than half of directors are independent

Össur Launches New POWER KNEE

Össur hf. Announces Sales Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.027 (vs US$0.017 in 1Q 2020)

Össur Hf. Provides Financial Guidance for the Full Year 2021

Vice Chairman Kristján Ragnarsson has left the company

Full year 2020 earnings released: EPS US$0.015 (vs US$0.16 in FY 2019)

Revenue misses expectations

Össur hf., Annual General Meeting, Mar 08, 2022

Laboratoires Innothera S.A.S completed the acquisition of Gibaud SAS from Össur hf. (CPSE:OSSR).

Össur Hf. Withdraw Its Financial Guidance for 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin